An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

Recruiting

Phase 2

NGM120An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

Sponsor:

NGM Biopharmaceuticals, Inc

Code:

NCT07033026

Conditions

Colorectal Cancer

CRC (Colorectal Cancer)

Cancer Cachexia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

NGM120 Q4W

NGM120 Q8W

Placebo given

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-30. This information was provided to ClinicalTrials.gov by NGM Biopharmaceuticals, Inc on 2025-06-27.